<DOC>
	<DOCNO>NCT00363376</DOCNO>
	<brief_summary>The specific aim study evaluate efficacy , tolerability , safety zonisamide therapy prevention weight gain associated olanzapine treatment psychotic bipolar disorder .</brief_summary>
	<brief_title>A Study Zonisamide Prevent Olanzapine-Associated Weight Gain</brief_title>
	<detailed_description>This single center , 16-week , randomize , double-blind , placebo-controlled , parallel group , flexible-dose study 60 outpatient schizophrenia , schizoaffective disorder , schizophreniform disorder , delusional disorder , psychotic disorder NOS , bipolar disorder type I , II , NOS DSM-IV-TR criteria43 BMI &gt; 22 treatment olanzapine ( 5-20 mg/day ) would appropriate monotherapy adjunctive therapy . Subjects meet entry criterion randomize treatment olanzapine plus zonisamide olanzapine plus placebo . All subject receive Personal Wellness Solution Counseling ( http : //www.zyprexa.com/hcp/hcp_patient_c_solutions_print.jsp ) . Both randomization zonisamide placebo , patient permit major psychotropic medication ( antipsychotic , mood stabilizer , antidepressant , anxiolytic ) add medication regimen . The primary outcome measure change weight . Secondary outcome measure include Young Mania Rating Scale ( YMRS ) ,44 Inventory Depressive Symptoms ( IDS ) ,45 Positive Negative Symptoms Scale ( PANSS ) ,46 Clinician Global Improvement ( CGI ) scale,47 Binge Eating Scale ( BES ) 48 , BMI , waist circumference , metabolic variable ( fast lipid , glucose , insulin ) . Subjects inpatients outpatient time randomization olanzapine-zonisamide olanzapine-placebo . Throughout study , psychiatric scale use assess psychiatric symptom , presence treatment-emergent adverse event monitor record .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Criteria enter study include follow : 1 . Subjects must 18 year age old . 2 . Subjects must schizophrenia , schizoaffective disorder , schizophreniform disorder , delusional disorder , psychotic disorder NOS , bipolar I , II , NOS disorder define DSMIVTR criterion . 3 . Subjects must BMI &gt; 22 . 4 . Subjects must sign Informed Consent Document nature trial fully explain . 5 . If female , subject must : postmenopausal , surgically incapable childbearing , practice medically acceptable effective method ( ) contraception ( e.g. , hormonal method , intrauterine device ) least one month prior study entry throughout study . 6 . If expose olanzapine past , subject must free olanzapine &gt; 3 month prior randomization study medication . Criteria exclusion study follow : 1 . Subjects clinically significant suicidal homicidal ideation . 2 . Subjects current DSMIV Axis I diagnosis delirium , dementia , amnesia , cognitive disorder ; psychotic mood disorder secondary substance use general medical disorder ; DSMIV diagnosis substance use disorder within past six month . 3 . Cardiovascular , endocrine , neurologic , hematologic disease determine clinical judgment clinical investigator . Subjects hypo hyperthyroidism unless stabilize thyroid replacement &gt; 3 month . 4 . Subjects allergic demonstrate hypersensitivity significant adverse event olanzapine . 5 . Subjects allergic demonstrate hypersensitivity zonisamide . 6 . Women pregnant nursing . 7 . Subjects receive experimental drug use experimental device within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>olanzapine</keyword>
	<keyword>zonisamide</keyword>
	<keyword>weight gain</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>psychotic disorder</keyword>
</DOC>